PET scan and blood test to see if radiotherapy with or without immunotherapy works
Part of Cancer, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests a special PET scan and blood tests to see how well tumors respond to a type of radiation therapy, with or without the immunotherapy drug pembrolizumab. It aims to find better ways to predict if the treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with one of these cancers: clear cell renal cell carcinoma, melanoma, cervical cancer, endometrial cancer, or triple negative breast cancer.
- You are not able to have curative treatments, but you are eligible for palliative radiation therapy.
- Your overall health is good, as measured by the Karnofsky scale (60-100%).
- You have at least one tumor that is larger than 5 cm and can be treated with a special radiation technique.
- You are over 18 years old and able to give informed consent.
- You are expected to live more than 6 months, and you have no contraindications to pembrolizumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan (68Ga-FAPI-46) to see if it can predict how well chemotherapy plus immunotherapy (pembrolizumab) works in people with triple-negative breast cancer before surgery. It aims to help doctors understand if the treatment is effective earlier.
This trial tests a new type of PET scan (Granzyme B-PET) to see if it can predict how well immunotherapy will work for people with triple-negative breast cancer that has spread. If it works, doctors might be able to tell sooner whether treatment is helping.
This trial uses a special PET scan to see how immune cells (CD8 T cells) are working in your tumor before you start a PD-1 immunotherapy drug (nivolumab or cetrelimab). The goal is to find out if the scan can predict whether the immunotherapy will work for you.
This study uses a special PET imaging scan to help doctors see how well pembrolizumab (an immunotherapy drug) is working against advanced non-small cell lung cancer. You'll receive the scan along with your regular pembrolizumab treatment and possible radiation therapy to help measure treatment response.
This trial tests a new combination of radiation plus an immunotherapy drug (pembrolizumab) to help your immune system fight metastatic triple-negative breast cancer after a prior immunotherapy has stopped working. The goal is to see if adding radiation can boost your body's response to treatment.
This early (Phase 1) study uses a special PET scan to measure how your immune system responds after stereotactic body radiation therapy (SBRT). The goal is to see whether the scan result can serve as a marker of immune response, which may help future treatment planning.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.